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Abstract 
Langerhans cell histiocytosis (LCH), which is a rare granulomatous pediatric disease of unknown etiology, is 
characterized by the idiopathic proliferation and accumulation of abnormal and clonal Langerhans cells or their 
marrow precursors, resulting in localized, solitary or multiple destructive lesions. These lesions are most commonly 
eosinophilic granuloma, which are found in craniofacial bone structures such as the skull and mandible, skin and 
other organs. In children, the disease has a variable initial presentation, and the clinical course, prognosis and sur-
vival are unpredictable. The aims of this report were to present an LCH case in a girl aged 2 years, 8 months and 
her clinicopathological features, to describe the bucodental management provided, and to discuss special dental 
considerations of this disease.
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Introduction
Langerhans cell histiocytosis (LCH), previously named 
histiocytosis X, is an uncommon hematological disease 
that predominantly affects infants and young children. 
LCH is characterized by a proliferation, infiltration and 
accumulation of a specific histiocyte, namely, the pa-
thological Langerhans cell, which is considered to be 
a special type of dendritic mononuclear cell, within a 
variety of tissues and organs (1,2). Such dendritic mo-
nonuclear cells are derived from the bone marrow and 
possess important immunologic functions, particularly 
in antigen development of T-lymphocytes (3,4). The mo-
noclonal infiltration of Langerhans cells, together with 
other immune effector cells, causes localized destructive 
tissue lesions as a result of the cellular infiltration, which 
replaces bone and invades skin, mucosa and internal or-
gans (5,6).
The disease was firstly described in 1865 by Dr. Thomas 
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Smith, who reported the case of a 4 years old child with 
impetigo and three large bone defects on the calvary. In 
1868, the German physiologist Paul Langerhans obser-
ved several non-pigmented dendritic cells in the epider-
mis and mucous membrane, which he initially considered 
to be neuronal, and then corrected himself. Subsequently 
and independently of each other, Dr. Alfred Hand, Dr. 
Artur Schüller and Dr. Henry Christian described similar 
cases (7,8). In 1953, Dr. Louis Lichtenstein introduced 
the term ‘histiocytosis X,’ which characterized the di-
sease as a proliferation of histiocytes of unclear etiolo-
gy, and it was unknown whether it should be classified 
as a neoplastic, inflammatory or lipid disorder (9,10). In 
1987, the Histiocyte Society was founded with the colla-
boration of several international research organizations; 
since then, the society has established diverse standards 
regarding the definition, classification and general ma-
nagement of LCH (11). 
The pathogenesis of LCH remains unclear and poorly un-
derstood; however, according to Merglová et al, various 
etiologic factors have been proposed, such as neonatal 
infections, a skipped vaccination, exposure to solvents, 
and thyroid diseases (10). Approximately 200 new cases 
of LCH are diagnosed each year in the US, whereas in 
Western Europe, it is estimated that LCH occurs at a rate 
of 2 to 5 cases per million per year, primarily in children 
under the age of 15 (the incidence peaks between 1 year 
and 4 years, although some cases have been reported in 
newborns); 80% are Caucasian, and boys are affected 
more than girls, with a reported male:female ratio ran-
ging from 2:1 to 4.6:1. Approximately 99% of patients 
are diagnosed with type I or II variety. Its incidence is 
approximately 10% that of acute childhood leukemias 
(4,5,12).
-Search strategy
This review was based on a Medline-PubMed, Scopus, 
and Web of Knowledge searching, which was conduc-
ted to obtain papers published in English and Spanish 
languages, between June 1999 and December 2014, 
using the following MESH terms or key words, in di-
fferent combinations: “Langerhans”, “histiocytosis”, 
“children”, “dental management”. We also conducted 
a manual searching of relevant papers published in four 
major oral surgery journals (Journal of Craniomaxillo-
facial Surgery, Oral Maxillofacial Surgery, Oral Surgery 
Oral Medicine Oral Pathology Oral Radiology Endo-
dontology, and Medicina Oral Patología Oral Cirugía 
Bucal), and three pediatric dentistry journals (Pediatric 
Dentistry, Journal of Clinical Pediatric Dentistry, Inter-
national Journal of Paediatric Dentistry). Both electronic 
and manual searching yielded in total sixty-seven poten-
tially relevant papers, based on the review of the corres-
ponding abstracts. Then, following the full-text critical 
evaluation, thirty-three studies were finally included in 
the review.
Case Report 
A Mexican girl aged 2 years, 8 months presented to the 
Dental Clinic, referred by a general dental practitioner, 
with a chief complaint of “strongly decayed, painful tee-
th and gum bleeding ”. Previously to the examination 
a written informed consent was obtained. The parents 
did not report craniofacial trauma, medication use, en-
vironmental allergies, or previous surgeries. From the 
age of 1 ½ years, the patient manifested recurrent episo-
des of skin erythema and rash, otitis media, anemia and 
fever. After complete medical and dental evaluation, a 
skin biopsy was collected and an immunohistochemical 
analysis was performed, which demonstrated positive 
results for CD 1a (d10, Labvision) and for S-100 (Poli-
clonal, DAKO). 
Subsequently, an imaging survey was performed: frontal 
(anteroposterior) and lateral cranial x-rays, and a 3-di-
mensional CAD view of cranial bones. The skull x-rays 
and 3-dimensional model exhibited two well-defined 
bone lesions with demarcated borders: the first lesion 
appeared in the right-central portion of the frontal bone, 
approximately 1 cm wide, ovoid form and divided into 
two cavities by a thin bone ridge; and the second lesion 
appeared in the left temporal bone, 3 mm wide, circular 
form, 1 cm from the orbit in the horizontal plane (Fig. 1). 
Additionally, the patient exhibited hepatomegaly, sple-
nomegaly, and bone marrow cell infiltration. Based on 
the data collected, the child was diagnosed with LCH.
Fig. 1. Frontal and lateral radiograph of the skull showing a punched-
out lesion in the frontal and temporal bone (arrows). A 3-dimensional 
CAD view of cranial bones of the same patient demonstrating oste-
olytic lesions (arrows).
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At the time of the first dental examination in our clinic, 
the patient was receiving chemotherapy, and did not re-
port any symptoms or discomfort related to the disease 
or treatment. When she was physically examined, the 
patient exhibited good general health status and a mar-
kedly uncooperative behavior. Except for her thinning 
hair, there was no evidence of abnormal extraoral signs 
(Fig. 2). 
Fig. 2. Extraoral view.
The patient’s oral cavity exhibited an almost completely 
erupted deciduous dentition, with mild incisor crowding, 
poor hygiene, excessive plaque accumulation, and hali-
tosis; none of the teeth demonstrated abnormal mobility. 
Soft tissue did not exhibit any abnormality. Deep carious 
cavities were present in both lower and left upper first 
molars, the right upper second molar and canine, and 
root remnants of the first right upper molar. The parents 
mentioned that she had moderate dental pain during ea-
ting. Approximately 1 year ago, they noted the presence 
of a soft “small bulge” in the palatal area, which resol-
ved spontaneously in a few months. 
Considering the patient´s age, her poor cooperation, 
and chemotherapy, we decided to conduct the entire 
oral rehabilitation under general anesthesia, once she 
was considered to be systemically stable. The parents 
fully understood and agreed with the treatment plan, and 
they provided written informed consent. The treatment 
consisted of performing five pulpotomies, which were 
then restored with stainless steel preformed crowns; the 
extraction of root remnants, and the subsequent positio-
ning of a band loop space maintainer. Additionally, pit 
and fissure sealants were placed on both partially erup-
ted lower second molars (Fig. 3). The process of general 
anesthesia followed the strict guidelines recommended 
by the American Academy of Pediatric Dentistry, in 
terms of care to minimize risks for the child. There were 
no adverse local or systemic events during and after the 
treatment. At subsequent appointments, the parents re-
ceived instructions regarding their daughter’s oral hy-
giene and nutritional guidance. Future control reviews 
were carefully scheduled. 
Fig. 3. a) Frontal intraoral view; b) Intraoral view of maxillary arch; 
c) Intraoral view of mandibular arch.
Patients’ parents accepted that their correspondent case 
report were submitted to a scientific dental journal, by 
means of a given signed written consent, after authors 
clearly and completely informed them about the possible 
benefits to dental science, in terms of knowledge and ge-
neration of research hypothesis for future higher quality 
studies.
Discussion
Traditionally, the International Histiocyte Society has 
classified LCH into three different types, based on the 
different clinical manifestations: Type I, Eosinophilic 
granuloma (chronic focal LCH), which only involves a 
solitary or multiple bone lesions; Type II, Hans-Schüller-
Christian disease (chronic disseminated LCH), which is 
characterized by the classical triad:  lytic bone lesions, 
exophthalmos, and diabetes insipidus; and Type III, Abt-
Letterer-Siwe disease (acute disseminated LCH), consi-
dered as the malignant form of LCH (2,8,12). However, 
because clinical findings are widely manifested, the di-
sease has also been classified into unifocal and multifo-
cal forms according to the extent of its spread throughout 
the body. The unifocal form presents only one destructi-
ve lesion in an organ, affecting more frequently tissues 
such as bones or skin (80% of cases), liver, spleen, brain, 
and lymph nodes (6). 
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The type of osteolytic localized lesion most common in 
pediatric LCH is the eosinophilic granuloma. Although 
the disease can cause lesions in any bone, previous ob-
servational studies have shown that head and neck are 
the most common anatomical areas where LCH bone le-
sions are present, with an incidence rate of 65% to 90%, 
including the skull (particularly the calvarium, temporal 
bones, and the sella turcica), mandible or maxilla (5,13).
Quaishi et al. (14) performed a study (between 1959 to 
1993) that included 73 British pediatric patients with 
LCH and found 67% of patients with head and neck in-
volvement, primarily manifested as localized bony le-
sions in the skull. Similarly, in a 10-year retrospective 
study on patients under 14 years old with LCH, Cochra-
ne et al. (15) reported that 57% of these patients exhibi-
ted localized osteolytic lesions, most frequently (67%) in 
the head and neck regions; the remaining 43% manifes-
ted the multifocal presentation of the disease. In another 
retrospective study (with an 18-year follow-up period) 
with 22 pediatric patients conducted by Buchmann et al. 
(16), 17 patients had head and neck involvement, and in 
14 patients these lesions were the primary bodily mani-
festation. Artzi et al. (17) mentioned that LCH patients 
with head and neck lesions manifested characteristic sig-
ns and symptoms of the periodontal disease. Thus, the 
evidence of destructive periodontitis, abnormal mobility 
or tooth loss as the initial child’s complaints during the 
primary dentition stage may be indicative of a systemic 
condition, such as LCH; for purposes of confirming the 
diagnosis using immunofluorescence tests, it is strongly 
recommended that the dentist collect sufficient gingi-
val biopsy material, with or without tooth extraction. In 
2009, from their case-and-control research, Alexiou et 
al. (18) reported 22 cases of children with skull solitary 
eosinophilic granuloma, who were predominantly male, 
had a mean age of 7.5 years, and in whom the frontal 
bone was the most commonly involved. 
Radiographically, the bone lesions usually appear as well 
defined central destructive-related radiolucencies; in the 
skull, these lesions develop in the diploic space, with 
sharply circumscribed, scalloped or confluent edges, 
or show a “button sequestrum.” (13,19). Flat and long 
bones, ribs, pelvis and shoulder blade are also affected; 
these type of lesions may cause pain and adjacent soft-
tissue swelling, especially during exercise. In the mul-
tifocal form, more than one organ is involved and may 
include other anomalies, such as hepatosplenomegaly, 
pulmonary disease, and cervical lymphadenopathy; oc-
casionally, the disease is related to otitis, deafness, leu-
kocytosis, fever, and endocrine gland and central ner-
vous system involvement (8,10). 
The initial LCH manifestations are often skin and oral 
changes. Seborrheic skin lesions or atopic dermatitis 
are observed in 38% of pediatric patients. In addition, 
the oral cavity may be the only affected area and the 
incidence of oral lesions is as frequent as 77%. Oral le-
sions may be the initial clinical signs or complaints in 
all forms of LCH, and 10-20% of them are considered to 
be nonspecific for the disease (6,19,20). Gingivitis with 
hyperplasia, bleeding, recession and necrosis, mucosal 
ulcerations and destruction of the alveolar bone and pe-
riodontal support, impaired healing, abnormal primary 
dentition mobility (‘floating teeth’), intraoral mass, ha-
litosis, and odontalgia are common findings in pediatric 
patients (12,21). Furthermore, lytic bone lesions in the 
jaw are predominant (5% to 10% of cases), primarily 
in the posterior region (distal to the canines) and ramus 
of the mandible, occasionally accompanied by facial 
pain and swelling, and in severe cases, pathological jaw 
fractures; they may disturb the tooth-germ development 
and cause enamel hypoplasia of the permanent teeth 
(3,22,23). Other facial, oral abnormalities and bone le-
sions are described in Table 1.
Through a clinical, imagenological and histopathologi-
cal examination, a definitive diagnosis of LCH can be 
established. Certain immunohistochemical findings are 
considered to be characteristic of the disorder, such as 
high levels of salivary interleukin-Iβ and prostaglan-
din E2, positive staining for S100 protein, Langerin 
(CD207) monoclonal antibody, and identification of 
specific cytoplasmic organelles known as Birbeck’s 
granules, or the CD1 antigen on the surface of the Lan-
gerhans cell (10,20,24). Other systemic abnormalities 
with similar clinical manifestations include leukemia, 
cyclic neutropenia, hypophosphatasia, fibrous dysplasia, 
Papillon-Lefèvre syndrome, agranulocytosis, malignant 
neoplasms, sarcoidosis, and giant cell disorders (3,5).
In dentistry, the primary differential diagnoses include 
advanced periodontal disease, diabetes-associated or a 
periapical process of dental or periodontal origin (3).
Although a specific therapeutic protocol for LCH does 
not exist, the Histiocyte Society published in 2009 the 
Evaluation and Treatment Guidelines based on current 
best practices in the treatment of LCH (25). In general, 
available treatment options include combinations of sur-
gical removal of localized bone lesions, chemotherapy 
and radiation (6). Diverse agents (immunosuppressant 
agents, immune modulators, and cytostatic agents) have 
been employed, such as corticosteroids, antibiotics, 
prednisone-vinblastine combination, vincristine sulpha-
te, indomethacin, methotrexate, cyclophosphamide, 
indomethacin, adrenocorticotropic hormone (ACTH), 
etoposide, and 6-mercaptopurine (26,27); or therapeutic 
procedures, such as interferon or cyclosporine-A, bone 
marrow transplant, monoclonal anti-CD 1a antibody the-
rapy, and gene transfer into hemopoietic progenitor or 
stem cells (26). Treatment of the disease depends prima-
rily on a careful multidisciplinary evaluation and correct 
diagnosis. According to the Histiocyte Society, the three 
points of confidence for a precise diagnosis of LCH in 
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Table 1. Features associated with Langerhans cell histiocytosis.
children are as follows: 1) clinical and radiographic oral 
characteristics, for example, displaced teeth and deve-
loping permanent tooth follicles with altered eruption 
patterns or dentoalveolar growth; 2) two or more posi-
tive stains for adenosinetriphosphatase, S-100 protein, 
alpha-D-mannosidase, or presence of peanut lectin; and 
3) detection of Birbeck granules and CD 1a antigen (T6) 
on the surface of Langerhans cells. Once the diagnosis 
is confirmed, the treatment team must perform skeletal 
and visceral system assessments to verify the presence 
of other lesions in the rest of the patient’s body (6,10). 
In general, the long-term craniofacial management of 
patients with LCH starts with a review of the natural 
history of the specific disorder, location, and therapeutic 
scheme currently administered (22,27). Bartnick et al. 
(28) recommended adhering to the staging of disease to 
determine the appropriate treatment plan and prognosis 
as follows: Stage I, a unique lesion; stage II, multiple 
lesions; and stage III, concurrent lesions in the craniofa-
cial region and other organs. Additionally, the clinicians 
must consider whether the lesions are located in bone or 
soft tissues or within the internal organs. Thus, in stages 
I and II, when only the bone or only the soft tissues are 
involved, the treatment is solely surgical. In stage III, a 
combination of chemotherapy, radiation (in recommen-
ded doses of 6 Grays to 15 Grays), and pharmacotherapy 
(1,26). However, in young pediatric patients, especially in 
those under 5 to 6 years of age, radiation therapy may se-
riously affect the developing teeth and craniofacial bones, 
as well as adversely affect the intellectual development; 
Authors, year Facial and oral manifestations Bone lesions
Henry et al. (20) Soft tissue lesions in the maxillary left primary first mo-
lar area, mobility of teeth, alveolar expansion, jaw pain, 
facial swelling
Expansion of the left alveolus surrounding the 
maxillary left primary first molar, multiple radio-
lucent lesions of the skull, numerous lytic lesions
Hernández-Juyol et al. (32) Not reported Lytic lesions in the skull and jaws
Mitomi et al. (29) Swelling of the head and exophtalmus, swelling of the 
mucogingival folds in the upper and lower primary mo-
lar regions
Multiple osteolytic lesions of the skull and man-
dible
Buchmann et al. (16) Not reported Bone lesions in calvarial, temporal bone, skull 
base, maxilla and mandible
Torrungruang et al. (21) Severe periodontal destruction, including inflamed 
gingiva, significant tooth mobility, deep pockets, pro-
nounced gingival recession, lack of attached gingiva
Extensive alveolar bone loss around primary mo-
lars, with the appearance of “teeth floating in the 
air”
Guimarães et al. (3) Bilateral maxillary left primary first molar area, mobili-
ty of teeth, alveolar expansion, jaw pain, facial swelling
Severe bone loss and poor osseous implantation, 
and “floating teeth”
Moraes et al. (23) Tooth mobility and gingival tissue  with  granular tex-
ture and easy bleeding 
Severe bone resorption, “teeth floating in space,” 
huge radiolucent, circumscribed and sharp unifo-
cal image on both sides of the mandible
Davis et al. (31) Not reported A right-sided frontal and anterior ethmoid sinus le-
sion with bone destruction and extension into the 
right orbit
Moralis et al. (26) Swelling of the left cheek and vestibule, limited mouth 
opening 
Bone erosion in the area of the left mandibular 
angle
Alexiou et al. (18) Mild swelling in the anterior mandible, mild mobility of 
the mandibular incisors
Destructive punched-out lesion
Park et al. (27) Slight limitation in mouth opening, tenderness on palpa-
tion of the left temporomandibular joint area
Severe destruction with absence of marginal bone 
of the left condyle, osteolytic destruction of the left 
temporomandibular joint
Martínez et al. (33) Tooth mobility, necrosis areas Osteolytic lesions with well-defined edges, and 
“floating teeth”
Alshadwi et al. (11) Mild swelling in the anterior mandible, mild mobility of 
the mandibular incisors
Large expansible radiolucent mass with displace-
ment of the mandibular teeth
Merglová et al. (10) Primary upper molars prematurely erupted with exces-
sive mobility, gingival and mucosa swelling  and ulcer-
ation 
Not reported
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hence, radiation therapy is not suggested as the first-choice 
treatment in young children. Additionally, in LCH stage III 
cases, there is a long-term 1-5% risk of secondary malig-
nancy, such as lymphoma, acute leukemia or solid tumors 
(10). Therefore, a more conservative drug therapy is prefe-
rred, for instance, intralesional corticosteroids (26); howe-
ver, this approach may occasionally delay the root develop-
ment of those teeth close to the osteolytic lesion (29).
The different available dental or craniofacial surgical 
treatment options for children with LCH have several 
aims, one of the most important being to provide not 
only functional results but also an esthetic orofacial 
appearance to prevent likely psychological sequelae and 
thus improve the patients’ quality of life (20,23). A com-
mon dental intervention is the extraction of primary tee-
th with severe mobility or in cases of osteolytic lesions 
surrounding the root apex; afterwards, it will be neces-
sary to attempt the recovery of subsequent lost vertical 
dimension (3). Another important treatment aim related 
to the dental occlusion is to avoid any likely interference 
during the permanent teeth eruption (23).
The prognosis of LCH depends on three specific indica-
tors (10,20): 1) Age: children under two years generally 
have disseminated disease and a poorer prognosis; 2)
Number of sites involved: multifocal disease (especially 
when spleen, lungs, liver, or the hematopoietic system 
are infiltrated) indicates a poorer prognosis. In children 
under 2 years of age with multifocal dysfunction invol-
vement, the disorder is considered to be life-threatening, 
with a mortality rate of approximately 60%; and 3) Organ 
dysfunction, when present, results in a poorer prognosis. 
On the other hand, LCH stages I and II have shown cure 
rates up to 80%, whereas in stage III, the rate decreases 
between 2% and 25%; the overall 5-year survival rate 
for LCH is approximately 92% (1,11). Although cases 
of spontaneous remission over a period of many mon-
ths or years have been observed, several cases have a 
long-lasting course with remissions, recurrences or dis-
seminations. Lau et al. (30) reported an incidence of 
permanent sequel in 29% of surviving patients, such as 
diabetes insipidus, exophtalmus, orthopedic anomalies, 
hearing loss, and neurological abnormalities; in several 
cases, such sequelae manifested up to 10 years after the 
initial diagnosis of LCH. It has been reported that the 
disorder dissemination (unifocal to multifocal) is most 
frequent in children under 5 years of age, within the first 
6 months after the initial diagnosis (6,23).
The long-term dentofacial development of children 
treated for LCH has not been fully reported; however, 
dentists and parents should be aware of the different che-
moradiation sequelae, primarily in children under 5 and 
6 years old; commonly reported anomalies include the 
following: localized enamel defects, tooth agenesia, al-
tered dentoalveolar growth, adverse intellectual effects, 
and second tumor development (3,20).
As mentioned above, although not always pathogno-
mic, oral findings in hard and soft tissues, such as local 
pain, swelling and ulcerations, may be the first or only 
clinical pathological manifestations of Langerhans cell 
histiocytosis. These oral changes should be of special 
interest for dentists because they may play a critical role 
in detecting LCH, and they are usually the first clini-
cians to examine the child’s oral cavity and participate 
in the diagnosis and care processes of the disease. An 
early diagnosis and appropriate referral are significant 
because the disease is, for the most part, fatal in severe 
cases. In addition to those clinical findings, it is essential 
to perform an image (radiographs and computer views) 
examination from the skull in suspected patients; howe-
ver, it is difficult to make a diagnosis without confirma-
tory immunohistochemical tests, such as a positive CD 
1a or S-100, because LCH bone lesions may be easily 
confounded with a malignant process, which results in 
unnecessary and likely aggressive management (18,27). 
In contrast, a more serious anomaly may be overlooked; 
for instance, Davis et al. (31) reported a case of an 11-
year-old male, in whom a lytic lesion located in the 
front-orbital and anterior ethmoid sinus bones was mi-
micking an aggressive osteomyelitis (Pott’s puffy tu-
mor). Therefore, the treatment team must make a careful 
and well-defined diagnosis to provide an adequate the-
rapeutic approach, maintaining the most optimal quality 
of life, with the fewest side-effects.
Conclusion
Dentists may play in important role in the multidiscipli-
nary treatment team that manages children with LCH, by 
performing careful early oral examinations and long-term 
controls during the follow-up period of the disease, for 
detecting associated oral findings, which may be the ini-
tial and only manifestations of the disorder. Therefore, cli-
nicians must be always vigilant to discern dental and mu-
cosal abnormalities in their patients with suspected LCH.
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